116 related articles for article (PubMed ID: 10688110)
1. When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
Frohlich DE; Chen JL; Neuberg D; Kehoe KM; Van den Abbeele AD
J Nucl Med; 2000 Feb; 41(2):269-74. PubMed ID: 10688110
[TBL] [Abstract][Full Text] [Related]
2. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
Janicek M; Kaplan W; Neuberg D; Canellos GP; Shulman LN; Shipp MA
J Clin Oncol; 1997 Apr; 15(4):1631-7. PubMed ID: 9193363
[TBL] [Abstract][Full Text] [Related]
3. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
5. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.
Gasparini M; Bombardieri E; Castellani M; Tondini C; Maffioli L; Devizzi L; Gerundini P
J Nucl Med; 1998 Sep; 39(9):1586-90. PubMed ID: 9744348
[TBL] [Abstract][Full Text] [Related]
6. Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma?
Champion PE; Groshar D; Hooper HR; Palmer M; Catz Z; Belch A; McEwan A
Nucl Med Commun; 1992 Oct; 13(10):730-7. PubMed ID: 1491837
[TBL] [Abstract][Full Text] [Related]
7. Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake.
Even-Sapir E; Bar-Shalom R; Israel O; Frenkel A; Iosilevsky G; Haim N; Epelbaum R; Gaitini D; Kolodny GM; Front D
J Clin Oncol; 1995 Apr; 13(4):942-6. PubMed ID: 7707122
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
[TBL] [Abstract][Full Text] [Related]
10. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Anderson JR; Harrison KA; Dalrymple GV; Byar K; Kessinger A; Armitage JO
J Clin Oncol; 1996 Sep; 14(9):2473-9. PubMed ID: 8823325
[TBL] [Abstract][Full Text] [Related]
11. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
[TBL] [Abstract][Full Text] [Related]
12. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.
Miller TP; Dahlberg S; Cassady JR; Adelstein DJ; Spier CM; Grogan TM; LeBlanc M; Carlin S; Chase E; Fisher RI
N Engl J Med; 1998 Jul; 339(1):21-6. PubMed ID: 9647875
[TBL] [Abstract][Full Text] [Related]
14. 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma.
Zijlstra JM; Hoekstra OS; Raijmakers PG; Comans EF; van der Hoeven JJ; Teule GJ; Jonkhoff AR; v Tinteren H; Lammertsma AA; Huijgens PC
Br J Haematol; 2003 Nov; 123(3):454-62. PubMed ID: 14617005
[TBL] [Abstract][Full Text] [Related]
15. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
Israel O; Mekel M; Bar-Shalom R; Epelbaum R; Hermony N; Haim N; Dann EJ; Frenkel A; Ben-Arush M; Gaitini D
J Nucl Med; 2002 Oct; 43(10):1295-303. PubMed ID: 12368366
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
17. Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome.
Ha CS; Choe JG; Kong JS; Allen PK; Oh YK; Cox JD; Edmund E
Cancer; 2000 Sep; 89(6):1371-9. PubMed ID: 11002233
[TBL] [Abstract][Full Text] [Related]
18. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
[TBL] [Abstract][Full Text] [Related]
19. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
20. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
Blayney DW; LeBlanc ML; Grogan T; Gaynor ER; Chapman RA; Spiridonidis CH; Taylor SA; Bearman SI; Miller TP; Fisher RI;
J Clin Oncol; 2003 Jul; 21(13):2466-73. PubMed ID: 12829664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]